about
Shining a light in the black box of orphan drug pricingPublication practices and standards: recommendations from GSK Vaccines' author survey.Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers.Epidemiological trends for hospital admissions for acute rotavirus gastroenteritis in Belgium following the introduction of routine rotavirus vaccination and the subsequent switch from lyophilized to liquid formulation of Rotarix™.Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries.Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum.Measuring what matters to rare disease patients - reflections on the work by the IRDiRC taskforce on patient-centered outcome measures.A mixed treatment comparison of gabapentin enacarbil, pramipexole, ropinirole and rotigotine in moderate-to-severe restless legs syndrome.Regulatory watch: The orphan drug pipeline in Europe.Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest GroupMarket watch: Are orphan drug companies the pick of the pharmaceutical industry?Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort
P50
Q33602241-1774B8DA-968D-4D55-AF77-738FD27B722AQ34584753-5BCB2946-2010-488A-8043-15480631BB6FQ36937790-627127E6-AD80-4264-9BD4-615DD6199879Q37367123-2A43748D-B8B6-4793-B8B8-0E1AB1AC2538Q37441285-544CCA12-427A-4CEE-9CD8-482F06789FACQ45960757-F188A347-7876-42AB-B7C9-873AB922D3B2Q47102105-9B469F51-C441-4554-A424-FEF9107AB731Q51065399-4E91BB69-EFF8-4B23-A0CE-DD601D565E38Q54257787-87FD08F2-8EAE-40C9-AE14-565536D27A65Q64045547-A56D5AF1-7AEA-498A-AEC6-1D3893EDDE27Q87016048-81D8F414-70A1-4E60-AFA2-803C0C619D84Q91904764-BF57D1B5-FD3E-4273-AA44-7BD00D940D72
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
研究者
@zh
name
Thomas Morel
@ast
Thomas Morel
@en
Thomas Morel
@es
Thomas Morel
@nl
type
label
Thomas Morel
@ast
Thomas Morel
@en
Thomas Morel
@es
Thomas Morel
@nl
prefLabel
Thomas Morel
@ast
Thomas Morel
@en
Thomas Morel
@es
Thomas Morel
@nl
P1153
55583176100
P31
P496
0000-0002-0690-5359